Advertisement

Diuretics pp 141-172 | Cite as

Discovery and Development of Diuretic Agents

  • H.-J. Lang
  • M. Hropot
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 117)

Abstract

The history of diuretics goes back a long way. It is believed that paleolithic man discovered the caffeine-containing plants. Beverages containing caffeine were prepared from the seeds and bark of different plants. Xanthine derivatives and osmotic diuretics were also used due to their clinically important diuretic effects before the emergence of modern diuretics.

Keywords

Loop Diuretic Ethacrynic Acid Aldosterone Antagonist Diuretic Effect Phenoxyacetic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackerman DM, MacLean AG, Brady MM, Kraml M (1990) AY-31906, a novel high ceiling diuretic with potassium sparing properties. In: Puschett JB, Greenberg A (eds) Diuretics III: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, pp 94–96Google Scholar
  2. Allison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM (1987) The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 41:282–288PubMedCrossRefGoogle Scholar
  3. Axelrod DR, Pitts RF (1952) The relationship of plasma pH and anion pattern to mercurial diuresis. J Clin Invest 31:171–179PubMedCrossRefGoogle Scholar
  4. Baldwin JJ, Ponticello GS, Sugrue MF (1989) MK-417. Drugs Future 14:636–638Google Scholar
  5. Beyer KH (1958) The mechanism of action of chlorothiazide. Ann NY Acad Sci 71:363–379PubMedCrossRefGoogle Scholar
  6. Beyer KH, Baer JE (1961) Physiological basis for the action of newer diuretic agents. Pharmacol Rev 13:517–562PubMedGoogle Scholar
  7. Beyer KH, Baer JE, Michaelson JK, Russo HF (1965) Renotropic characteristics of ethacrynic acid: a phenoxy-acetic saluretic-diuretic agent. J Pharmacol Exp Ther 147:1–22PubMedGoogle Scholar
  8. Bianco S, Vaghi A, Robuschi M, Pasargiklian M (1988) Prevention of exercise-induced bronchoconstriction by inhaled furosemide. Lancet II: 252–255CrossRefGoogle Scholar
  9. Bouley E, Teulon JM, Cazes M, Cloarec A, Deghenghi R (1986) p-(Thienylcar- bonyl)amino-phenoxy propanolamine derivatives as diuretic and beta-adrenergic receptor blocking agents. J Med Chem 29:100–103PubMedCrossRefGoogle Scholar
  10. Brater DC (1979) Renal sites of action of azosemide. Clin Pharmacol Ther 25:428–434PubMedGoogle Scholar
  11. Brooks DP, Koster PF, Albrightson CR, Huffman WF, Moore ML, Stassen FL, Schmidt DB, Kinter LB (1989) Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements. Eur J Pharmacol 160:159–162PubMedCrossRefGoogle Scholar
  12. Burg M, Stoner L, Cardinal J, Green N (1973) Furosemide effect on isolated perfused tubules. Am J Physiol 225:119–124PubMedGoogle Scholar
  13. Campbell DB, Moore RA (1981) The pharmacology and clinical pharmacology of indapamide. Postgrad Med J 57 [Suppl 2]:7–17PubMedGoogle Scholar
  14. Cragoe EJ Jr, Woltersdorf OW, Bicking JB, Kwong SF, Jones JH (1967) Pyrazine diuretics. II. N-amidino-3-amino-5-substituted 6-halopyrazines. J Med Pharm Chem 10:66–75CrossRefGoogle Scholar
  15. Cragoe EJ Jr, Woltersdorf OW Jr, Gould NP, Pietruszkiewicz AM, Ziegler C, Sakurai Y, Stokker GE, Anderson PS, Bourke RS, Kimelberg HK, Nelson LR, Barron KD, Rose JR, Szarowski D, Popp AJ, Waldman JB (1986) Agents for the treatment of brain edema 2. [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-lH- fluoren-7-yl)oxy]alkanoic acids and some of their analogues. J Med Chem 29: 825–841PubMedCrossRefGoogle Scholar
  16. Cushny AR, Lambie CG (1921) The action of diuretics. J Physiol (Lond) 55:276–286Google Scholar
  17. Davenport H, Wilhelmi AE (1941) Renal carbonic anhydrase. Proc Soc Exp Biol Med 48:53–56Google Scholar
  18. DeGasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J (1989) Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 32:223–227CrossRefGoogle Scholar
  19. Delarge J (1988) Chemistry and pharmacological properties of the pyridines- sulfonylurea derivative torasemide. Arzneimittelforschung/Drug Res 38(I):144–150Google Scholar
  20. Dodson RM, Tweit RC (1959) Addition of alkanethiolic acids to delta1 4-3-oxo- and delta46-3-oxosteroids. J Am Chem Soc 81:1224CrossRefGoogle Scholar
  21. Engel K, Epstein T (1931) Die Quecksilberdiurese. Ergebn Inn Med Kinderheilkd 40:187–261CrossRefGoogle Scholar
  22. Fagard R, Lijnen P, Moerman E, Staessen J, Amery A (1987) Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension. Eur J Clin Pharmacol 32:71–75PubMedCrossRefGoogle Scholar
  23. Fanelli GM Jr, Bohn DL, Scriabine A, Beyer Jr DH (1977) Saluretic and uricosuric effects of (6,7-dichloro-2-methyl-l-oxo-2-phenyl-5-indanyloxy) acetic acid (MK- 196) in the chimpanzee. J Pharmacol Exp Ther 200:402–412PubMedGoogle Scholar
  24. Feit PW (1971) Aminobenzoic acid diuretics 2,4-substituted-3-amino-5-sulfamyl- benzoic acid derivatives. J Med Chem 14:423–439CrossRefGoogle Scholar
  25. Geek P, Pietrzyk C, Burckhardt BC, Pfeiffer B, Heinz E (1980) Electrically silent cotransport of Na+, K+ and Cl- in Ehrlich cells. Biochim Biophys Acta 600:432–447CrossRefGoogle Scholar
  26. Gennari FJ, Kassirer JP (1974) Osmotic diuresis. N Engl J Med 291:714–720PubMedCrossRefGoogle Scholar
  27. Greger R, Schlatter E, Lang F (1983) Evidence of electroneutral sodium chloride cotransport in the cortical thick ascending limb of Henle’s loop of rabbit kidney. Pflugers Arch 396:308–314PubMedCrossRefGoogle Scholar
  28. Gerber A, Weidmann P, Bianchetti MG, Ferrier C, Laederach K, Mordasini R, Riesen W, Bachmann C (1985) Serum lipoproteins during treatment with the antihypertensive agent indapamide. Hypertension 7 [Suppl 2]:II164—II169PubMedGoogle Scholar
  29. Greger R, Nitschke RB, Lohrmann E, Burhoff I, Hropot M, Englert HC, Lang HJ (1991) Effects of arylaminobenzoate-type chloride channel blockers on equivalent short-circuit current in rabbit colon. Pflugers Arch 419:190–196PubMedCrossRefGoogle Scholar
  30. Greven J, Heidenreich O (1978) Effects of ozolinone, a diuretic active metabolite of etozolin, on renal function. I. Clearance studies in dogs. Naunyn Schmiedebergs Arch Pharmacol 304:283–287PubMedCrossRefGoogle Scholar
  31. Guinot Ph, Frölich JC (1985) Study of the effects of cycletanine on prostanoids. Arzneimittelforschung/Drug Res 35(11): 1714–1716Google Scholar
  32. Haberey M, Buse M, Losert W, Nishino Y (1986) Mespirenone a novel aldosterone antagonist. Naunyn Schmiedebergs Arch Pharmacol 334 [Suppl]: Abstr 109Google Scholar
  33. Helgeland A (1980) The Oslo Study. Am J Med 69:725–732PubMedCrossRefGoogle Scholar
  34. Higaki J, Harada H, Tonda K, Hirata M (1989) Chemical structure and toxicity of diuretics in isolated hepatocytes. Pharmacol Toxicol 65(l):21–24PubMedCrossRefGoogle Scholar
  35. Hropot M, Muschaweck R (1992) Chemistry and chemical classification of diuretics. In: Reyes AJ (ed) Progress in pharmacology and clinical pharmacology, vol 9. Fischer, Stuttgart, p 3Google Scholar
  36. Hropot M, Englert HC, Granzer E, Kerékjártó von B, Klaus E, Lang HJ, Scholz W (1990) HOE 708, a novel diuretic with hypolipidemic properties. In: Puschett JB, Greenberg A (eds) Diuretics III: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, pp 117–123Google Scholar
  37. Hropot M, Lang HJ, Alpermann HG, Hainz P (1991) Neurokinin A-induced chloride secretion is inhibited by a chloride channel blocker in canine tracheal epithelium. Naunyn Schmiedebergs Arch Pharmacol 343 [Suppl]:R46Google Scholar
  38. Johnston PA, Kau ST (1993) A micropuncture study on the renal site of action of ICI 206,970, a unique eukalemic diuretic. J Pharmacol Exp Ther 264:604–608PubMedGoogle Scholar
  39. Kau ST (1992) Basic pharmacology and pharmacological classification of diuretics. In: Reyes AJ (ed) Progress in pharmacology and clinical pharmacology, vol 9. Fischer, Stuttgart, pp 33–113Google Scholar
  40. Keddie JR, Collins MG (1989) The diuretic and saliuretic properties of PD 116948, a potent adenosine receptor antagonist. Br J Pharmacol 97 [Suppl]:502PGoogle Scholar
  41. Kirsten R, Alexandridis T, Heintz B, Hopf R, Nelson K, Pooth R, Sievert H (1986) Acute influence of piretanide on hemodynamics and vasoactive hormones in patients with congestive heart failure. In: Puschett JB, Greenberg A (eds) Diuretics II: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, p 365Google Scholar
  42. Kobayashi T, Mizumoto H, Karasawa A, Kubo K (1992) Diuretic and antihypertensive properties of KW-3902, a novel adenosine Al receptor antagonist. Jpn J Pharmacol 58 [Suppl l]:195pGoogle Scholar
  43. Kubota J, Kubo S, Nishimura H, Ureyama M, Kino M, Nakayama A, Hara M, Kawamura K (1989) Cardiorenal effects of an orally active dopamine prodrug (T-870) in patients with congestive heart failure. J Cardiovasc Pharmacol 14:53–57PubMedCrossRefGoogle Scholar
  44. Lant A (1985a) Diuretics, clinical pharmacology and therapeutic use, part I. Drugs 29:57–87PubMedCrossRefGoogle Scholar
  45. Lant A (1985b) Diuretics, clinical pharmacology and therapeutic use, part II. Drugs 29:162–188PubMedCrossRefGoogle Scholar
  46. Lawrence JR, Ansari AF, Elliot HL, Sumner DJ, Brunton GF, Whiting B, Whitesmith R (1978) Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther 23:558–565PubMedGoogle Scholar
  47. Leander JD, Hart JC, Zerbe RL (1987) kagonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels. J Pharmacol Exp Ther 242:33–39PubMedGoogle Scholar
  48. Loew D, Meng K (1977) The renal mechanism of Bay-g-2821. Pharmatherapeutica 1:333–340Google Scholar
  49. Maass AR, Snow IB, Erickson R (1978) Ticrynafen: an antihypertensive, diuretic, uricosuric agent. In: Cragoe EJ Jr (ed) Diuretic agents. ACS, Washington DC, p 84 (ACS symposium series 83)CrossRefGoogle Scholar
  50. Mann T, Keilin D (1940) Sulfanilamide as a specific inhibitor of carbonic anhydrase. Nature 146:164–165CrossRefGoogle Scholar
  51. Manning M, Lammek B, Kolodziejczyk AM, Seto J, Sawyer WH (1981) Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine vasopressin. J Med Chem 24:701–706PubMedCrossRefGoogle Scholar
  52. Maren TH, Mayer E, Wadsworth BC (1954) Carbonic anhydrase inhibition. I. The pharmacology of Diamox; 2-acetylamino-l,3,4-thiadiazole-5-sulfonamide. Bull Johns Hopkins Hosp 95:199–243PubMedGoogle Scholar
  53. Merkel W, Bormann D, Mania D, Muschaweck R, Hropot M (1976) Piretanide (Hoe 118) a new high-ceiling salidiuretic. Eur J Med Chem 11(5):399–406Google Scholar
  54. Miller GE, Danzig LS, Talbott JH (1951) Urinary excretion of uric acid in the dalmatian and non-dalmatian dog following administration of diodrast, sodium salicylate and a mercurial diuretic. Am J Physiol 164:155–158PubMedGoogle Scholar
  55. Muschaweck R, Hajdú P (1964) Die salidiuretische Wirksamkeit der Chlor-N-(2-furylmethyl)-5-sulfamyl-anthranilsäure. Arzneimittelforschung/Drug Res 14(1): 44–47Google Scholar
  56. Mutschler E, Knauf H, Finke M, Kraft H, Möhrke W, Priewer H, Ullrich F, Völger KD, Vollmer G (1987) Pharmacodynamics and pharmacokinetics of investigational triamterene derivatives. In: Puschett JB, Greenberg A (eds) Diuretics II: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, p25Google Scholar
  57. Nakamura M, Kawabata T, Itoh T, Miyata K, Harada H (1990) Stereoselective saluretic effect and localization of renal tubular secretion of enantiomers of S-8666, a novel uricosuric antihypertensive diuretic. Drug Dev Res 19:23–36CrossRefGoogle Scholar
  58. Novello FC, Sprague JM (1957) Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc 79:2028–2029CrossRefGoogle Scholar
  59. Ozawa N, Mori N (1986) The effects of a dopamine prodrug TA 8704 on improvement of kidney function. Jpn J Pharmacol 40 [Suppl]:127Google Scholar
  60. Pamnani MB, Haddy FJ, Bryant HJ, Swindall BT, Horn GJ, Johnston J, Cragoe EJ Jr (1986) Effects of 6-iodo-amiloride, a sodium channel blocker, on cardiovascular parameters in spontaneously hypertensive Wister-Kyoto rats. J Hypertens 4 [Suppl 3]:S491-S493Google Scholar
  61. Plattner JJ, Fung AKL, Parks JA, Pariza RJ, Crowley SR, Pernet AG, Bunnell PR, Dodge PW (1984) Substituted 5,6-dihydrofurol(3,2-f)-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity. J Med Chem 27:1016–1026PubMedCrossRefGoogle Scholar
  62. Pocchiari F, Pataccini R, Castelnovo P, Longo A, Casagrande C (1986) Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetcs in rats. Arzneimittelforschung/Drug Res 26(IIa):334–340Google Scholar
  63. Roussel Uclaf Investigators’ Brochure (1992) Internal report. Roussel Uclaf, RomainvilleGoogle Scholar
  64. Sandström PE, Sehlin J (1988) Furosemide reduces insulin release by inhibition of Cl - and Ca2+ fluxes in β-cells. Am J Physiol 255:E591-E596PubMedGoogle Scholar
  65. Satzinger G, Herrmann M, Vollmer KO, Merzweiler A, Gomahr H, Heidenreich O, Greven J (1978) Etozolin: a novel diuretic. In: Cragoe EJ Jr (ed) Diuretic agents. ASC, Washinigton DC, pp 155–189 (ASC symposium series 83)CrossRefGoogle Scholar
  66. Saxl P, Heilig R (1920) Über die diuretische Wirkung von Novasurol und anderen Quecksilberinjektionen. Wien Klin Wochenschr 42:943–944Google Scholar
  67. Scholz W, Albus U, Lang HJ, Linz W, Martorana PA, Englert HC, Schölkens BA (1993) Hoe 694, a new Na+/H+ exchange inhibitor and its effects in cardiac ischaemia. Br J Pharmacol 109:562–568PubMedGoogle Scholar
  68. Schwartz WB (1949) The effect of sulfanilamide on salt and water excretion in congestive heart failure. N Engl J Med 240:173–177PubMedCrossRefGoogle Scholar
  69. Slizgi GR, Ludens JH (1982) Studies on the nature and mechanism of diuretic activity of the opioid analgesic ethylketazocine. J Pharmacol Exp Ther 220:585–591PubMedGoogle Scholar
  70. Strauss MB, Southworth H (1938) Urinary changes due to sulfanilamide administration. Bull Johns Hopkins Hosp 63:41–45Google Scholar
  71. Sturm K, Siedel W, Weyer R, Ruschig H (1966) Zur Chemie des Furosemids. I. Synthesen von 5-sulfamoyl-anthranilsäure-Derivaten. Chem Ber 99:328–344CrossRefGoogle Scholar
  72. Sturm K, Muschaweck R, Hropot M (1983) 5-Sulfamoylorthanilic acids, a sulfonamide series with salidiuretic activity. J Med Chem 26:1174–1187PubMedCrossRefGoogle Scholar
  73. Takagi S, Takayama S, Onodera T (1990) Effects of DR-3438, tienilic acid, in-dacrynone and furosemide on primary cultured hepatocytes from rats. In: Puschett JB, Greenberg A (eds) Diuretics III: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, p 800Google Scholar
  74. Tanaka M, Hashimoto H, Tanaka S, Masura M, Shirasaki Y, Akashi A (1990) Pharmacological profile of DR-3438, a new uricosuric diuretic. In: Puschett JB, Greenberg A (eds) Diuretics III: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, p 150Google Scholar
  75. Vigne P, Frelin C, Cragoe EJ Jr, Lazdunski M (1983) Ethylisopropyl-amiloride: a new and highly potent derivative of amiloride for the inhibition of the Na+/H+ exchange system in various cell types. Biochem Biophys Res Commun 116:86–90PubMedCrossRefGoogle Scholar
  76. Wales JK, Grant A, Wolff FW (1968) Studies on the hyperglycemic effects of nonthiazide diuretics. J Pharmacol Exp Ther 159:229–235PubMedGoogle Scholar
  77. Wangemann Ph, Braitsch R, Greger R (1987) The diuretic effect of muzolimine. Pflugers Arch 410:674–676PubMedCrossRefGoogle Scholar
  78. Wiebelhaus VD, Brennan FT, Sosknowski G, Maas AR, Weinstock J, Bender AD (1967) The natriuretic and diuretic characteristics of triamterene in the dog. Arch Int Pharmacodyn Ther 169:429–451PubMedGoogle Scholar
  79. Yamaguchi I, Nishiyama S, Akimoto Y, Yoshikawa M, Nakajima H (1989) A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol 13:879–886PubMedCrossRefGoogle Scholar
  80. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, Tominaga M, Yabuuchi Y (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105: 787–791PubMedGoogle Scholar
  81. Yamasaki F, Notsu T, Kitamoto A, Shinkawa T, Inhabe H, Mochida E, Yoshitomi K, Imai M (1990) A novel potent diuretic, M 17055, having both loop and distal actions. In: Puschett JB, Greenberg A (eds) Diuretics III: chemistry, pharmacology, and clinical applications. Elsevier Science, New York, pillGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • H.-J. Lang
  • M. Hropot

There are no affiliations available

Personalised recommendations